Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
Ping XuJunhua Xu

Abstract

To evaluate the efficacy and safety of the introduction of moxifloxacin into the recommended regimen for tuberculosis (TB) treatment. A meta-analysis was performed of nine eligible studies regarding the effect of moxifloxacin plus the recommended regimen compared to the recommended regimen alone for the treatment of TB. In the efficacy analysis, the overall odds ratio (OR) for sputum culture conversion was 1.895 (95% confidence interval (CI) 1.355-2.651, p=0.000), indicating that when moxifloxacin is combined with the recommended regimen, the rate of sputum culture conversion is elevated compared to the recommended regimen alone. The overall OR for recurrence was 0.516 (95% CI 0.342-0.920, p=0.022), suggesting that the introduction of moxifloxacin into the recommended regimen reduces TB relapse after treatment. In the safety analysis, the overall OR was estimated to be 1.001 (95% CI 0.855-1.172, p=0.989), demonstrating that adding moxifloxacin to the recommended regimen does not cause more adverse events during TB treatment. This meta-analysis suggests that the introduction of moxifloxacin into the recommended regimen for the treatment of non-drug resistant TB improves the clinical outcome by elevating the culture conversion ra...Continue Reading

References

Oct 8, 1999·The Journal of Antimicrobial Chemotherapy·S H Gillespie, O Billington
Mar 16, 2001·Current Opinion in Investigational Drugs·J F Barrett
May 6, 2006·American Journal of Respiratory and Critical Care Medicine·William J BurmanRichard E Chaisson
May 2, 2009·American Journal of Respiratory and Critical Care Medicine·Susan E DormanUNKNOWN Tuberculosis Trials Consortium
Nov 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James A SeddonH Simon Schaaf
May 1, 2013·Nature Reviews. Drug Discovery·Alimuddin ZumlaStewart T Cole
Jul 17, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Banurekha V VelayuthamJawahar M Shaheed
Sep 10, 2014·The New England Journal of Medicine·Stephen H GillespieUNKNOWN REMoxTB Consortium
Oct 23, 2014·The New England Journal of Medicine·Amina JindaniUNKNOWN RIFAQUIN Trial Team
Mar 24, 2015·Tuberculosis·S TheeH S Schaaf
Mar 27, 2015·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·J D FonsecaT D McHugh

❮ Previous
Next ❯

Citations

Oct 16, 2019·Antimicrobial Agents and Chemotherapy·Samantha DonnellanGiancarlo A Biagini
Oct 7, 2018·BMC Infectious Diseases·Liesbeth F MierasMarieke G G Sturkenboom
Nov 3, 2020·Chemistry, an Asian Journal·Chitrala Teja, Fazlur Rahman Nawaz Khan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.